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High Levels of (Un)Switched Memory B Cells Are Associated With
Better Outcome in Patients With Advanced Atherosclerotic Disease
John A. L. Meeuwsen, MSc; Amerik van Duijvenvoorde, MSc; Aisha Gohar, MD; Maria O. Kozma, BSc; Sander M. van de Weg, BSc;
Crystel M. Gijsberts, MD, PhD; Saskia Haitjema, MD, PhD; Harry Bj€orkbacka, PhD; Gunilla N. Fredrikson, PhD; Gert J. de Borst, MD,
PhD; Hester M. den Ruijter, PhD; Gerard Pasterkamp, MD, PhD; Christoph J. Binder, MD, PhD; Imo E. Hoefer, MD, PhD;
Saskia C. A. de Jager, PhD
Background-—Atherosclerosis is an inﬂammatory lipid disorder and the main underlying pathology of acute ischemic events.
Despite a vast amount of data from murine atherosclerosis models, evidence of B-cell involvement in human atherosclerotic
disease is limited. We therefore investigated the association of circulating B-cell subtypes with the occurrence of secondary
cardiovascular events in advanced atherosclerotic disease.
Methods and Results-—This cohort study consists of 168 patients who were included in the Athero-Express biobank between
2009 and 2011. Before surgery, peripheral blood mononuclear cells were isolated and stored in liquid nitrogen. After gentle
thawing of the peripheral blood mononuclear cells, different B-cell subtypes including na€ıve, (un)switched memory, and
CD27+CD43+ B1-like B cells, were analyzed by ﬂow cytometry. Univariable and multivariable Cox proportional hazard models were
used to analyze associations between B-cell subtypes, circulating antibodies and secondary cardiovascular manifestations during
the 3-year follow-up period. Mean age was 70.19.6 years, males represented 62.8% of the population, and 54 patients had
secondary manifestations during follow-up. High numbers of unswitched memory cells were protective against secondary outcome
(hazard ratio, 0.30 [95% CI, 0.13–0.69]; P<0.01). Similar results were obtained for the switched memory cells that also showed to
be protective against secondary outcome (hazard ratio, 0.33 [95% CI, 0.14–0.77]; P=0.01).
Conclusions-—A high number of (un)switched memory B cells is associated with better outcome following carotid artery
endarterectomy. These ﬁndings suggest a potential role for B-cell subsets in prediction and prevention of secondary cardiovascular
events in patients with atherosclerosis. ( J Am Heart Assoc. 2017;6:e005747. DOI: 10.1161/JAHA.117.005747.)
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A lthough the prevention of cardiovascular disease (CVD)has improved in the past decades, it remains one of the
major causes of death worldwide.1 Its main underlying
pathology, atherosclerosis, is an inﬂammatory lipid disorder
and the major cause of acute cardiovascular syndromes.2–4
Many inﬂammatory cell types, including monocytes, macro-
phages, mast cells, neutrophils, and T and B cells, have been
implicated in the initiation, progression, and destabilization of
atherosclerosis.5 Increased insights into how these inﬂam-
matory cells are involved in CVD may lead to the identiﬁcation
of novel biomarkers or therapeutic targets for primary or
secondary manifestations of CVD.
The risk of cardiovascular events is particularly high in
patients with earlier CVD manifestations.6,7 For example, the
3-year cumulative incidence of major adverse cardiovascular
events in patients undergoing carotid endarterectomy was
13%.8 Increased inﬂammation is an important risk factor for
recurrent CVD events.2 For example, different studies showed
that high white blood cell counts are associated with the
recurrence of CVD events and mortality.9–13 These studies,
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however, mainly consider total white blood cell count or total
lymphocyte counts and do not provide additional information
regarding cell-speciﬁc subtypes.
Besides their well-known role in humoral immunity through
antibody production, B cells are important for T-cell activation
and cytokine production inmaintaining immune homeostasis.14
The total peripheral B-cell pool in humans mainly consists
of na€ıve B cells, CD43+ B1-like cells,15–17 unswitched and
switched memory cells (mainly expressing immunoglobulin [Ig]
M,18 or IgG and IgA antibodies, respectively18), regulatory B
cells, and plasma cells. As such, B cells are important in immune
homeostasis, but have also been shown to be detrimental in
autoimmune diseases like common variable immunodeﬁciency
and systemic lupus erythematosus.19,20 Interestingly, patients
with these B-cell-driven autoimmune diseases are also at high
risk for CVD.19,20
Evidence for an important role of B lymphocytes in human
CVD is limited. In patients with acute myocardial infarction (MI),
high levels of the B-cell speciﬁc cytokines, chemokine (C-C
motif) ligand 7 and B-cell activating factor, predict increased
risk of death and recurrent MI.21 In addition, hypertensive
patients with high percentages of CD40+ B cells were at lower
risk for stroke,22 whereas high numbers of CD86+ B cells
showed higher risk for stroke.22 A larger body of evidence is
derived from elaborate mouse studies, which identiﬁed a
subset-speciﬁc role for B lymphocytes in atherosclerosis.23–25
To date, it is generally accepted that (auto)antibody-producing
B1 B cells are atheroprotective26,27 and this protective effect
depends on IgM secretion,28 whereas conventional B2 B cells
are generally considered proatherogenic.29 This proathero-
genic phenotype in mice has mainly been attributed to the
production of pathogenic IgG antibodies against oxidized low-
density lipoprotein (oxLDL) and the immune effector function of
these B cells.27,28,30–33 In human atherosclerosis, however,
there is conﬂicting evidence about the role of autoantibodies
directed against oxLDL. On the one hand, oxLDL antibodies
have been associatedwith the presence34 and progression35–37
of atherosclerosis and the risk for MI. On the other hand, anti-
oxLDL autoantibodies have also been associated with lower
oxLDL levels38 and decreased carotid atherosclerosis as well.39
In addition, vaccination with a pneumococcal vaccine, mimick-
ing oxLDL epitopes, was shown to attenuate atherosclerotic
lesion formation in mice40 and, according to a recent meta-
analysis, also prevents CVD in adults.41
Taken together, accumulating evidence points to an
important role of B cells in CVD, but human evidence is
limited. In order to establish whether a speciﬁc B-cell proﬁle is
associated with secondary cardiovascular events, we mea-
sured circulating B-cell subtypes, including na€ıve, CD43+
B1-like, unswitched, and switched memory B cells, as well as
oxLDL antibodies, in severe atherosclerotic patients derived
from the Athero-Express biobank. B-cell subtypes were
identiﬁed by ﬂow cytometry and associated with the occur-
rence of secondary cardiovascular manifestations during
follow-up after carotid endarterectomy.
Materials and Methods
Study Population
This study includes a subcohort of 168 patients from the
Athero-Express biobank, a cohort study of patients under-
going carotid endarterectomy that were included between
2009 and 2011.42 In addition to the standard procedure,
including an extensive patient questionnaire and detailed
histological plaque characterization, peripheral blood
mononuclear cells (PBMCs) were isolated from blood that
was drawn preoperatively. Isolated PBMCs were stored in
liquid nitrogen until further analyses were performed. Patient
follow-up duration was 3 years or until the occurrence of
secondary cardiovascular events (cardiovascular death,
stroke, MI, coronary intervention, peripheral intervention
[including amputation], or a combination). All events were
validated using health records kept by general practitioners.
All patients provided written informed consent. The study
protocol conforms to the Declaration of Helsinki and has
been approved by the Institution’s ethics committee on
research on humans.
Blood Collection and PBMC Isolation
Twenty milliliters of blood were collected in Li-Heparin blood
tubes. A complete blood count proﬁle was determined by a
Clinical Perspective
What Is New?
• We show an extensive ﬂow cytometry proﬁling of B cells in
severe cardiovascular patients and associate this proﬁle to
risk for future events.
• We show, for the ﬁrst time, that both unswitched and
switched memory B cells associate with better outcome in
patients with existing cardiovascular disease.
• Oxidized low-density lipoprotein low-density lipoprotein IgG
autoantibody titers strongly correlate to memory B-cell
numbers, but oxidized low-density lipoprotein low-density
lipoprotein autoantibodies were not predictive for future
events.
What Are the Clinical Implications?
• These ﬁndings indicate that memory B cells might have
value in prediction and prevention of adverse secondary
cardiovascular manifestations.
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general hematology cell counter (Cell Dyn 1800; Abbott
Laboratories, Abbott Park, IL). Directly after collection, the
platelet-rich plasma fraction was isolated by centrifugation for
10 minutes at 150g at room temperature without brake. The
blood volume was restored to its original volume with PBS.
Subsequently, blood was gently layered on a Ficoll (17-1440-
03; GE Healthcare, Chalfont St. Giles, UK) loaded Leucosep
tube (227 290; Greiner bio-one, Alphen aan den Rijn, The
Netherlands) and centrifuged at 1000g for 15 minutes at
room temperature without brake. PBMCs were carefully
isolated from the interphase. To remove any residual Ficoll,
PBMCs were washed with cold PBS, centrifuged at 330g for
10 minutes at 4°C with brake, and resuspended in 1 mL of
sterile, serum-free cell freezing medium with DMSO (C6295;
Sigma-Aldrich, St. Louis, MO). PBMCs were slowly frozen
overnight at 80°C using a Nalgene freezing container and
stored in liquid nitrogen until further analyses were
performed.
Flow Cytometry
PBMCs were gently thawed and washed with RPMI 1640
([61870010; Gibco Carlsbad, CA] supplemented with Gluta-
Max, 25 nmol/L HEPES, 1% penicillin/streptomycin and 2%
FBS [10270-106; Gibco, Carlsbad, CA]). Cells were kept on ice
during the whole procedure, unless stated otherwise. To
obtain single-cell suspensions, PBMCs were gently ﬁltered
over a 40-lm cell strainer (542040; Greiner bio-one), washed
Table 1. Antibody Characteristics
Marker Fluorochrome Clone lL
IgD AF488 IA6-2 2.5
CD24 PE ML-5 2.5
CD19 PE-Cy5 HIB19 2.5
CD38 PE-Cy7 HIT2 2.5
CD43 APC 10G7 2.5
IgM APC-Cy7 MHM-88 5
CD27 PB O323 1
CD3 BV510 OKT3 1
Panel of antibodies used. All antibodies are from BioLegend (San Diego, CA). AF indicates
Alexa Fluor; APC, allophycocyanin; BV, brilliant violet; Ig, immunoglobulin; PB, paciﬁc
blue; PE, (R-)phycoerythrin.
Figure 1. Gating strategy for the selection of different B-cell subtypes from a representative sample. First,
dead cells and CD3+ T cells were excluded. Next, from the viable non-T cells, the CD19+ B cells were
identiﬁed. Then, the CD24lowCD38+ plasmablasts (PB) were excluded, and from the non-PB, the
CD43+CD27+ cells were selected. Next, based on surface expression of CD27 and IgD, class-switched
(CSM) and nonclass switched memory cells (NCSM) were identiﬁed. From the IgD+CD27 cells, the
CD38+CD24+ transitional and regulatory (Trans/Reg) could be distinguished from the na€ıve B cells. An
overview of the antibody characteristics is provided in Table 1. Ig indicates immunoglobulin.
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with RPMI again, and centrifuged at 350g for 5 minutes at
4°C. Subsequently, cells were resuspended in cold PBS
(supplemented with 2% FBS and 20 mmol/L of EDTA),
centrifuged at 350g for 5 minutes at 4°C, and resuspended
in cold PBS with 1% BSA. Subsequently, cells were incubated
with antibodies (Table 1) for 30 minutes at room temperature
in the dark, washed with PBS (4°C), and centrifuged at 350g
for 5 minutes at 4°C. Next, cells were incubated for
30 minutes with ﬁxable viability dye eFluor-506 (eBioscience,
San Diego, CA), washed, centrifuged, and measured on the
ﬂow cytometer (Gallios; Beckman Coulter, Fullerton, CA).
Analysis of the ﬂow cytometry data was performed using
Kaluza 1.3 software. We selected viable CD19+CD3 lympho-
cytes, excluded plasmablasts (CD24CD38+; Figure 1), and
gated CD43+CD27+ cells, which are suggested to resemble
B1 B cells.15 Next, we selected unswitched memory cells
(CD27+CD43IgD+) and switched memory cells
(CD27+CD43IgD). From the CD27IgD+ B cells, we
selected the na€ıve CD24+CD38+ B cells (Figure 1). Absolute
B-cell numbers were calculated from the ratio measured by
Table 2. Baseline Characteristics of the Study Cohort Stratiﬁed by Occurrence of Secondary Cardiovascular Events
Overall (n=168) No Events (n=114) Events (n=54) P Value
Age, y 70.19.6 69.89.3 70.910.3 0.50
Sex (% male) 108 (62.8) 72 (61.5) 36 (65.5) 0.74
Current smoker 61 (35.7%) 41 (35.3%) 20 (36.4%) 1
BMI 26.74.6 26.74.7 26.74.4 1
Contralateral stenosis 72 (47.7%) 45 (44.6%) 27 (54.0%) 0.36
Diabetes mellitus 41 (23.8%) 28 (23.9%) 13 (23.6%) 1
Hypercholesterolemia 106 (71.6%) 74 (70.5%) 32 (74.4%) 0.78
Hypertension 149 (86.6%) 100 (85.5%) 49 (89.1%) 0.68
CAD history 62 (36.0%) 41 (35.0%) 21 (38.2%) 0.82
Clinical manifestations 0.26
Asymptomatic 25 (14.5%) 13 (11.1%) 12 (21.8%)
Ocular 29 (16.9%) 19 (16.2%) 10 (18.2%)
Stroke 42 (24.4%) 31 (26.5%) 11 (20.0%)
TIA 76 (44.2%) 54 (46.2%) 22 (40.0%)
Medication
Statins 138 (80.2%) 92 (78.6%) 46 (83.6%) 0.57
Beta-blockers 82 (47.7%) 53 (45.3%) 29 (52.7%) 0.46
Anticoagulants 11 (6.4%) 5 (4.3%) 6 (10.9%) 0.11
Laboratory parameters
Total cholesterol, mmol/L 4.0 [3.3, 4.8] 4.0 [3.4, 4.7] 4.0 [3.3, 4.8] 0.75
Triglycerides, mmol/L 1.5 [1.1, 2.0] 1.4 [1.1, 1.9] 1.5 [1.1, 2.0] 0.54
HDL cholesterol, mmol/L 1.0 [0.9, 1.3] 1.0 [0.9, 1.2] 1.0 [0.9, 1.3] 0.15
LDL cholesterol, mmol/L 2.1 [1.6, 2.8] 2.2 [1.8, 2.9] 2.1 [1.6, 2.8] 0.20
hsCRP plasma, lg/mL 16.078.4 17.290.7 13.337.1 0.78
GFR MDRD, mL/min 69.518.3 70.517.4 67.320.2 0.31
WBC count (9106 cells/mL) 7.2 [5.5, 8.6] 7.0 [5.5, 8.9] 7.4 [5.6, 8.2] 0.99
Lymphocytes (9106 cells/mL) 1.5 [1.2, 2.1] 1.6 [1.2, 2.2] 1.4 [1.1, 1.9] 0.09
Monocytes (9106 cells/mL) 0.8 [0.6, 0.9] 0.8 [0.6, 1.0] 0.8 [0.6, 0.9] 0.59
Granulocytes (9106 cells/mL) 4.6 [3.4, 6.1] 4.4 [3.3, 6.1] 5.1 [3.5, 6.0] 0.34
The demographic characteristics of the study cohort are given for the whole population and also stratiﬁed by occurrence of secondary cardiovascular events. Values are presented as
meanSD for normal distributions, number of patients (frequency in percentage) for categorical variables, and median [interquartile range] for non-normal distributions. P values are
calculated using Student t tests, chi-square or Fisher’s exact tests, and Kruskal–Wallis tests, respectively. BMI indicates body mass index; CAD history, history of Coronary Artery Disease;
Contralateral stenosis, 50% to 100% stenosis of the contralateral carotid artery; GFR MDRD, glomerular ﬁltration rate according to the Modiﬁcation of Diet in Renal Disease formula; HDL,
high-density lipoprotein; hsCRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; TIA, transient ischemic attack; WBC, whole blood cell.
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ﬂow cytometry multiplied by the absolute number of lympho-
cytes obtained from the hematology cell counter.
Anti-oxLDL Antibody Measurements
Serum levels of IgM and IgG-a-oxLDL antibodies were
measured as described previously.40,43 In short, serum
samples were diluted 500 times for IgM and 2000 times
for IgG-a-oxLDL antibody measurements. Antibody titers
were determined by chemiluminescent enzyme immunoas-
says, and values are presented as relative light units per
100 ms.
Statistical Analysis
Normally distributed continuous variables are indicated as
meansSDs and compared by Student’s t tests or a 1-way
ANOVA. Non-normal distributed data are presented as
medians (interquartile ranges; IQRs) and were compared by
Kruskal–Wallis tests. Categorical variables were indicated as
percentages and compared by chi-square or Fisher’s exact
tests where appropriate. As confounders, we selected
variables that associate with CVD risk, but also inﬂuence B-
cell numbers and have been established as confounders in
literature, including age, sex, smoking, history of coronary
artery disease, and glomerular ﬁltration rate.22,44–47 We also
tested for a sex interaction between the association of B cells
and cardiovascular end points.
Univariable and multivariable Cox proportional hazard
models were used to study the association of B-cell
subtypes and anti-oxLDL antibodies with occurrence of
secondary cardiovascular events over time. Next, to visu-
alize this association, subjects were divided into tertiles
according to the absolute numbers of B-cell subtypes and
plotted against the occurrence of secondary cardiovascular
events over time. Data management and statistical analyses
were performed with RStudio48 and the R software
package49 (version 3.2.0.; R Foundation for Statistical
Computing, Vienna, Austria). P<0.05 was considered as
signiﬁcant.
Results
Clinical Characteristics
Baseline characteristics are shown in Table 2, stratiﬁed into
patients with and without secondary cardiovascular events. Of
the included 168 patients, 54 experienced secondary cardio-
vascular events during follow-up, which included cardiovas-
cular death (n=11), stroke (n=13), coronary events (n=11),
and peripheral intervention (n=35). Risk factors for the
presence of CVD, such as age, sex, smoking, and kidney
function (glomerular ﬁltration rate), did not differ between
patients with or without secondary events (Table 2).
Total B Cells and (Un)Switched Memory B Cells
Are Higher in Patients Without Secondary
Cardiovascular Events
We measured different B-cell subtypes using ﬂow cytometry.
Total B cell numbers (200 cells/lL) and B-cell subset
numbers corroborate with earlier observations50 (Table 3).
Next, we investigated whether baseline levels of B cells
differed between patients who developed secondary cardio-
vascular events during follow-up after endarterectomy (cases)
compared to those without a secondary event (controls;
Table 3). Total numbers of CD19+ B cells (167 [IQR, 115–236]
versus 209 [IQR, 121–415] cells/lL; P=0.04), unswitched
memory cells (8 [IQR, 4–12] versus 12 [IQR, 6–25] cells/lL;
P<0.01), and switched memory cells (21 [IQR, 13–34] versus
27 [IQR, 15–54] cells/lL; P=0.02) were lower in cases than in
controls. Although numbers of na€ıve B cells or CD43+CD27+ B
cells also tended to be higher, these differences were not
statistically signiﬁcant between groups. Baseline characteris-
tics of patients stratiﬁed by B lymphocyte tertiles are shown
in Table 4.
Associations of B-cell subtypes with univariate risk
factors
We then investigated whether the numbers of B cells or B-cell
subtypes were associated with cardiovascular risk factors. As
Table 3. Baseline Numbers of Total B Cells and B-Cell Subtypes Stratiﬁed By Occurrence of Secondary Cardiovascular Events
B-cell (Sub)Type (cells/lL) Surface Markers Overall (n=168) No Events (n=114) Events (n=54) P Value
B lymphocytes CD19+CD3 193 [121, 323] 209 [122, 415] 167 [115, 236] 0.04
B1 like CD27+CD43+ 8 [3, 15] 9 [4, 15] 7 [3, 13] 0.39
Unswitched CD27+CD43IgD+ 10 [5, 21] 12 [6, 25] 8 [4, 12] <0.01
Switched CD27+CD43IgD 26 [15, 47] 27 [16, 54] 21 [13, 34] 0.02
Na€ıve CD27CD43IgD+ 102 [58, 184] 106 [62, 213] 89 [56, 141] 0.17
The numbers of B cells are presented for the whole cohort and also stratiﬁed by occurrence of secondary cardiovascular events during follow-up. Absolute numbers of B cells and B-cell
subtypes with their surface markers are indicated as median [interquartile range]. P values were calculated using the Kruskal–Wallis test for nonparametric distributions.
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expected, total B-cell numbers decreased with age and were
higher in women and in current smokers. Speciﬁc associa-
tions of each B-cell subtype with the cardiovascular risk
factors are depicted in Table 5. We selected age, sex,
smoking, history of coronary artery disease, and glomerular
ﬁltration rate as potential confounders, based on their
established prognostic value in CVD.
Cox regression analysis of B cells with secondary
cardiovascular events
Because of the known B-cell-related immunological differ-
ences between sexes, we tested sex interaction between the
association of B cells and cardiovascular end points, but there
was no statistically signiﬁcant interaction. Univariable and
multivariable Cox proportional hazard regression models were
used to calculate the hazard ratios (HRs) for each B-cell
subset (Table 6). Patients were then categorized into tertiles
according to the absolute number of B cells and B-cell
subsets. Interestingly, patients with high numbers of
unswitched memory B cells were at lower risk of experiencing
a secondary cardiovascular event during follow-up as com-
pared with patients with low numbers (HR, 0.30 [95%
conﬁdence interval (CI), 0.13–0.69]; P<0.01; Figure 2). Like-
wise, patients in the highest tertile of switched memory cell
numbers were at lower risk than patients in the lowest tertile
(HR, 0.33 [95% CI, 0.14–0.77]; P=0.01). When we combined
Table 4. Baseline Characteristics of the Study Cohort Stratiﬁed By Tertiles of Total B Lymphocytes
Low (n=56) Intermediate (n=56) High (n=56) P Value
B Lymphocytes (cells/lL) 96 [67, 121] 193 [168, 214] 430 [326, 506]
Age, y 72.210.5 69.99.2 68.08.9 0.07
Sex (% male) 36 (64.3) 40 (71.4) 30 (53.6) 0.14
Current smoker 14 (25.5%) 21 (37.5%) 26 (46.4) 0.07
BMI 27.44.4 25.44.0 27.35.2 0.03
Contralateral stenosis 31 (59.6%) 18 (39.1%) 20 (40.8%) 0.07
Hypertension 49 (87.5%) 47 (83.9%) 49 (87.5%) 0.82
Diabetes mellitus 11 (19.6%) 11 (19.6%) 17 (30.4%) 0.30
Hypercholesterolemia 38 (77.6%) 27 (56.2%) 38 (79.2%) 0.02
CAD history 25 (44.6%) 17 (30.4%) 18 (32.1%) 0.23
Clinical manifestations 0.58
Asymptomatic 7 (12.5%) 9 (16.1%) 8 (14.3%)
Occular 12 (21.4%) 11 (19.6%) 6 (10.7%)
Stroke 10 (17.9%) 14 (25.0%) 17 (30.4%)
TIA 27 (48.2%) 22 (39.3%) 25 (44.6%)
Medication
Statins 48 (85.7%) 42 (75.0%) 46 (82.1%) 0.34
Beta-blockers 30 (53.6%) 24 (42.9%) 25 (44.6%) 0.48
Anticoagulants 2 (3.6%) 7 (12.5%) 2 (3.6%) 0.11
Laboratory parameters
Cholesterol, mmol/L 3.8 [3.2, 4.6] 4.1 [3.3, 4.9] 3.9 [3.4, 4.4] 0.71
Triglycerides, mmol/L 1.5 [1.2, 2.1] 1.4 [1.0, 1.9] 1.6 [1.2, 2.0] 0.30
HDL cholesterol, mmol/L 1.0 [0.9, 1.2] 1.0 [0.9, 1.3] 1.0 [0.9, 1.2] 0.72
LDL cholesterol, mmol/L 2.1 [1.6, 2.5] 2.1 [1.6, 3.1] 2.1 [1.6, 2.7] 0.60
hsCRP plasma, lg/mL 5.0 (15.7) 9.7 (29.6) 33.8 (130.8) 0.14
GFR MDRD, mL/min 66.0 (17.7) 74.8 (19.0) 68.8 (17.5) 0.04
The baseline characteristics are depicted for patients with low, intermediate and high numbers of total B lymphocytes. Values are presented as meanstandard deviation for normal
distributions, number of patients (frequency in percentage) for categorical variables, and median [inter-quartile range] for non-normal distributions. P-values are calculated using a one-way
ANOVA, Chi-square or Fisher’s exact tests, and Kruskal–Wallis tests, respectively. BMI indicates body mass index; CAD history, history of Coronary Artery Disease; Contralateral stenosis,
50% to 100% stenosis of the contralateral carotid artery; GFR MDRD, Glomerular ﬁltration rate according to Modiﬁcation of Diet in Renal Disease formula; HDL, high-density lipoprotein;
hsCRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; TIA, transient ischemic attack.
DOI: 10.1161/JAHA.117.005747 Journal of the American Heart Association 6
B Cells in Cardiovascular Disease Meeuwsen et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on O
ctober 16, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
Ta
bl
e
5.
U
ni
va
ria
bl
e
As
so
ci
at
io
ns
of
th
e
To
ta
lB
C
el
ls
an
d
B-
C
el
lS
ub
ty
pe
s
W
ith
C
la
ss
ic
al
C
ar
di
ov
as
cu
la
r
Ri
sk
Fa
ct
or
s
B
Ly
m
ph
oc
yt
es
(C
el
ls
/
l
L)
N
a€ ı
ve
(C
el
ls
/
l
L)
U
ns
w
itc
he
d
M
em
or
y
(C
el
ls
/
l
L)
Sw
itc
he
d
M
em
or
y
(C
el
ls
/
l
L)
C
D
43
+
C
D
27
+
(C
el
ls
/
l
L)
Be
ta
[9
5%
C
I]
P
Va
lu
e
Be
ta
[9
5%
C
I]
P
Va
lu
e
Be
ta
[9
5%
C
I]
P
Va
lu
e
Be
ta
[9
5%
C
I]
P
Va
lu
e
Be
ta
[9
5%
C
I]
P
Va
lu
e
Ag
e,
y
3
.1
4
[
6.
35
to
0.
07
]
0.
05
0
.4
9
[
2.
83
to
1.
85
]
0.
68
0
.5
[
0.
78
to
0.
22
]
<
0.
01
1
.1
3
[
1.
79
to
0.
46
]
<
0.
01
0
.4
[
0.
61
to
0.
19
]
<
0.
01
Se
x
(m
al
e)
7
4.
19
[
13
7.
92
to
10
.4
7]
0.
02
5
5.
49
[
10
1.
4
to
9.
58
]
0.
02
1
.7
4
[
7.
49
to
4.
02
]
0.
55
5
.3
5
[
18
.9
8
to
8.
28
]
0.
44
0
.4
[
4.
78
to
3.
97
]
0.
86
Cu
rr
en
t
sm
ok
er
72
.0
6
[7
.8
3–
13
6.
3]
0.
03
1.
83
[
45
.2
1
to
48
.8
7]
0.
94
9.
94
[4
.3
4–
15
.5
3]
<
0.
01
39
.4
9
[2
7.
14
–5
1.
84
]
<
0.
01
3.
39
[
0.
98
to
7.
77
]
0.
13
BM
I
1.
43
[
5.
36
to
8.
22
]
0.
68
1.
63
[
3.
26
to
6.
52
]
0.
51
0.
23
[
0.
37
to
0.
83
]
0.
45
0
.3
5
[
1.
78
to
1.
07
]
0.
63
0
[
0.
45
to
0.
46
]
0.
98
Co
nt
ra
la
te
ra
l
st
en
os
is
2
4.
9
[
85
.7
1
to
35
.9
1]
0.
42
1
0.
17
[
57
.2
8
to
36
.9
3]
0.
67
5
.2
2
[
11
.3
to
0.
85
]
0.
09
3
.1
4
[
12
.6
3
to
6.
34
]
0.
51
1
.3
5
[
6.
02
to
3.
32
]
0.
57
Di
ab
et
es
m
el
lit
us
65
.4
9
[
7.
81
to
13
8.
79
]
0.
08
53
.3
5
[0
.6
1–
10
6.
09
]
0.
05
0.
89
[
5.
7
to
7.
47
]
0.
79
3
[
12
.6
to
18
.6
]
0.
70
1.
84
[
3.
15
to
6.
83
]
0.
47
Hy
pe
rc
ho
le
st
er
ol
em
ia
21
.7
1
[
52
.4
5
to
95
.8
8]
0.
56
2.
27
[
50
.2
3
to
54
.7
8]
0.
93
3.
16
[
3.
76
to
10
.0
7]
0.
37
10
.2
4
[
6.
22
to
26
.6
9]
0.
22
3.
09
[
2.
05
to
8.
24
]
0.
24
Hy
pe
rte
ns
io
n
4
2.
66
[
13
3.
3
to
47
.9
8]
0.
35
2
5.
09
[
90
.5
2
to
40
.3
5]
0.
45
0
.8
9
[
8.
98
to
7.
2]
0.
83
1
3.
23
[
32
.3
to
5.
83
]
0.
17
2.
64
[
3.
49
to
8.
77
]
0.
40
CA
D
hi
st
or
y
5
3
[
11
7.
68
to
11
.6
9]
0.
11
2
2.
71
[
69
.6
1
to
24
.1
9]
0.
34
5
.1
9
[
10
.9
4
to
0.
56
]
0.
08
1
2.
09
[
25
.7
2
to
1.
53
]
0.
08
3
.0
6
[
7.
44
to
1.
32
]
0.
17
To
ta
lc
ho
le
st
er
ol
,
m
m
ol
/L
1
0.
87
[
42
.0
1
to
20
.2
7]
0.
49
1
4.
67
[
37
.0
7
to
7.
73
]
0.
2
1.
06
[
1.
64
to
3.
77
]
0.
44
1.
69
[
4.
83
to
8.
22
]
0.
61
1.
16
[
0.
91
to
3.
23
]
0.
27
Tr
ig
ly
ce
rid
es
,
m
m
ol
/L
5.
68
[
31
.3
4
to
42
.7
]
0.
76
4
.5
6
[
31
.2
9
to
22
.1
7]
0.
74
4.
22
[1
.0
7–
7.
37
]
0.
01
5.
79
[
1.
91
to
13
.5
]
0.
14
2.
14
[
0.
3
to
4.
58
]
0.
09
HD
L
ch
ol
es
te
ro
l,
m
m
ol
/L
3
.9
7
[
12
2.
77
to
11
4.
83
]
0.
95
2
6.
37
[
11
2.
05
to
59
.3
1]
0.
54
1
.1
8
[
11
.4
9
to
9.
13
]
0.
82
14
.0
7
[
10
.7
1
to
38
.8
5]
0.
26
2
.2
6
[
10
.1
6
to
5.
64
]
0.
57
LD
L
ch
ol
es
te
ro
l,
m
m
ol
/L
1
7.
96
[
56
.8
3
to
20
.9
1]
0.
36
1
4.
09
[
42
.2
1
to
14
.0
2]
0.
32
1
.7
9
[
4.
71
to
1.
13
]
0.
23
1
.9
7
[
10
.1
2
to
6.
19
]
0.
63
0.
2
[
2.
2
to
2.
6]
0.
87
hs
CR
P
pl
as
m
a,
l
g/
m
L
0.
04
[
0.
39
to
0.
47
]
0.
86
0.
03
[
0.
28
to
0.
34
]
0.
85
0
[
0.
04
to
0.
03
]
0.
91
0.
01
[
0.
08
to
0.
09
]
0.
87
0
[
0.
02
to
0.
02
]
0.
93
GF
R
M
DR
D,
m
L/
m
in
0.
59
[
1.
2
to
2.
38
]
0.
52
0
.0
9
[
1.
39
to
1.
2]
0.
89
0.
08
[
0.
07
to
0.
23
]
0.
31
0.
33
[
0.
05
to
0.
7]
0.
09
0.
02
[
0.
08
to
0.
11
]
0.
73
Th
e
as
so
ci
at
io
ns
be
tw
ee
n
ris
k
fa
ct
or
s
an
d
B
ce
ll
nu
m
be
rs
ar
e
pr
es
en
te
d
as
be
ta
[9
5%
co
nﬁ
de
nc
e
in
te
rv
al
s
(C
Is
)].
Fo
r
ca
te
go
ric
al
va
ria
bl
es
,b
et
a
is
th
e
di
ffe
re
nc
e
in
B-
ce
ll
nu
m
be
rs
(c
el
ls
/
l
L)
be
tw
ee
n
gr
ou
ps
.F
or
co
nt
in
uo
us
va
ria
bl
es
,b
et
a
is
th
e
lin
ea
r
re
gr
es
si
on
co
ef
ﬁ
ci
en
t
re
la
tin
g
a
1-
un
it
in
cr
ea
se
in
th
e
va
ria
bl
e
to
th
e
as
so
ci
at
ed
ch
an
ge
in
B-
ce
ll
nu
m
be
rs
.“
P
Va
lu
e”
is
th
e
P
va
lu
e
of
th
e
lin
ea
r
or
lo
gi
st
ic
re
gr
es
si
on
m
od
el
fo
r
as
so
ci
at
io
n.
BM
Ii
nd
ic
at
es
bo
dy
m
as
s
in
de
x;
C
AD
hi
st
or
y,
hi
st
or
y
of
C
or
on
ar
y
Ar
te
ry
D
is
ea
se
;C
on
tr
al
at
er
al
st
en
os
is
,5
0%
to
10
0%
st
en
os
is
of
th
e
co
nt
ra
la
te
ra
lc
ar
ot
id
ar
te
ry
;G
FR
M
D
RD
,G
lo
m
er
ul
ar
ﬁ
ltr
at
io
n
ra
te
ac
co
rd
in
g
to
M
od
iﬁ
ca
tio
n
of
D
ie
t
in
Re
na
lD
is
ea
se
fo
rm
ul
a;
H
D
L,
hi
gh
-d
en
si
ty
lip
op
ro
te
in
;
hs
C
RP
,
hi
gh
-s
en
si
tiv
ity
C
-r
ea
ct
iv
e
pr
ot
ei
n;
LD
L,
lo
w
-d
en
si
ty
lip
op
ro
te
in
.
DOI: 10.1161/JAHA.117.005747 Journal of the American Heart Association 7
B Cells in Cardiovascular Disease Meeuwsen et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on O
ctober 16, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
both the numbers of switched and unswitched memory cells,
patients in the highest tertile of total memory cells were still
at lower risk (HR, 0.35 [95% CI, 0.15–0.83]; P=0.02)
compared with patients in the lowest tertile of total memory
cells; however, the combination did not further decrease the
risk for recurrent CVD events as the HR was comparable.
Comparable results were obtained when we excluded
secondary surgical interventions from the composite end
point (25 end points remaining). In multivariable Cox propor-
tional hazard regression models, patients in the highest tertile
were at lower risk of events, now only consisting of
cardiovascular death, stroke, or MI, as compared with
patients in the lowest tertile (HR, 0.35 [95% CI, 0.15–0.82];
P=0.01) of unswitched memory cells and (HR, 0.32 [95% CI,
0.13–0.75]; P=0.01) of switched memory cells.
Surface IgM Expression Is Higher in Patients With
High Numbers of Unswitched Memory Cells
IgM has been shown to be atheroprotective in mouse
atherosclerosis models. To assess whether the protective
effect of the (un)switched memory B cells is reﬂected by high
expression of IgM, we measured surface expression of IgM.
Indeed, in patients with high numbers of unswitched memory
cells, surface expression of IgM was also higher as compared
with patients with low numbers of unswitched memory B cells
(median ﬂuorescence intensity, 62.5 [IQR, 51.2–70.0] versus
53.4 [IQR, 40.4–65.1]; P=0.03), suggesting that these
patients not only possessed higher numbers of unswitched
memory B cells, but that these cells also produce more IgM
antibodies.
Table 6. Cox Proportional Hazard Models of Total B Lymphocytes and B-Cell Subtypes
Patients (Events) Cells/lL
Univariable Multivariable
HR [95% CI] P Value HR [95% CI] P Value
Total B lymphocytes Continuous 0.98 [0.96–1.00] 0.01 0.98 [0.96–1.00] 0.01
56 (21) 40 to 141 Low 1 (Ref) 1 (Ref)
56 (21) 142 to 257 Intermediate 0.90 [0.49–1.66] 0.74 0.92 [0.48–1.75] 0.79
56 (12) 258 to 1351 High 0.5 [0.25–1.01] 0.05 0.47 [0.22–1.00] 0.05
Na€ıve Continuous 0.98 [0.95–1.00] 0.05 0.98 [0.95–1.00] 0.06
56 (22) 2 to 71 Low 1 (Ref) 1 (Ref)
56 (19) 72 to 141 Intermediate 0.80 [0.43–1.48] 0.48 0.82 [0.42–1.59] 0.56
56 (13) 141 to 759 High 0.53 [0.27–1.06] 0.07 0.59 [0.29–1.20] 0.15
Unswitched memory Continuous 0.75 [0.59–0.95] 0.02 0.63 [0.46–0.86] <0.01
56 (23) 1 to 6 Low 1 (Ref) 1 (Ref)
56 (21) 7 to 15 Intermediate 0.94 [0.52–1.7] 0.84 0.89 [0.47–1.67] 0.72
56 (10) 16 to 126 High 0.37 [0.18–0.79] <0.01 0.30 [0.13–0.69] <0.01
Class switched memory Continuous 0.86 [0.77–0.97] 0.02 0.80 [0.69–0.93] <0.01
56 (22) 1 to 17 Low 1 (Ref) 1 (Ref)
56 (20) 18 to 39 Intermediate 0.87 [0.47–1.59] 0.65 0.74 [0.39–1.42] 0.37
56 (12) 40 to 398 High 0.48 [0.24–0.96] 0.04 0.33 [0.14–0.77] 0.01
All memory Continuous 0.89 [0.82–0.97] <0.01 0.84 [0.75–0.93] <0.01
56 (21) 2 to 26 Low 1 (Ref) 1 (Ref)
56 (22) 27 to 60 Intermediate 1.05 [0.58–1.92] 0.86 0.88 [0.46–1.69] 0.70
56 (11) 61 to 447 High 0.47 [0.23–0.97] 0.04 0.35 [0.15–0.83] 0.02
CD43+/CD27+ Continuous 0.96 [0.77–1.18] 0.67 0.84 [0.61–1.16] 0.29
56 (20) 1 to 5 Low 1 (Ref) 1 (Ref)
56 (19) 6 to 12 Intermediate 0.86 [0.46–1.62] 0.65 0.88 [0.43–1.80] 0.72
56 (15) 13 to 116 High 0.68 [0.35–1.33] 0.26 0.71 [0.33–1.50] 0.36
Cox proportional hazard models are presented for different B-cell (subtype) numbers. In the continuous model, the hazard rate [95% conﬁdence interval (CI)] and P values is indicated per
increase of 10 cells/lL. In the other models, the intermediate or high tertile is compared to the low tertile in a univariable model or multivariable model adjusted for age, sex, smoking,
history of coronary artery disease, and glomerular ﬁltration rate.
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Serum Levels of Anti-oxLDL Autoantibodies
To further investigate the antibody production by these (un)
switched memory B cells, we determined antibody titers of
antibodies directed against oxLDL. Although there was no
correlation between IgM-a-oxLDL antibodies and memory B
cells, levels of IgG-a-oxLDL antibodies positively correlated
with class switched memory cells (spearman’s rho=0.28;
P<0.01; Figure 3). IgM- and IgG-a-oxLDL titers were not
signiﬁcantly increased in patients with a secondary CVD event
compared with those without (18 247 [IQR, 8809–35 064]
versus 16 982 [IQR, 8251–33 146] relative light units per
100 ms; P=0.67 for IgG-a-oxLDL, and 20 328 [IQR 11 706–
29 514] versus 22 111 [IQR 13 041–29 698] relative light
units per 100 ms; P=0.72 for IgM-a-oxLDL). When assessing
IgG-a-oxLDL antibodies in a Cox regression model, no
association with the risk for secondary CVD events was
found (HR, 1.01 [95% CI, 0.98–1.03]; P=0.67; data not
shown).
Discussion
We investigated the association of circulating B-cell subsets
with the occurrence of secondary cardiovascular events in
severe carotid atherosclerotic patients undergoing carotid
endarterectomy. We found that high levels of (un)switched
memory cells were independently associated with the free-
dom of recurrent cardiovascular events, suggesting that
patients with high numbers of (un)switched B cells are
protected against secondary cardiovascular manifestations.
Patients with autoimmune diseases, such as systemic lupus
erythematosus and common variable immunodeﬁciency, have
an increased risk of developing CVD. Production of (auto)
antibodies by B lymphocytes is a hallmark of autoimmune
disease and autoantibody formation is also evident in
atherosclerotic patients. SLE patients have reduced levels of
both switched and unswitched memory cells,19 and decreased
levels of unswitched memory cells are associated with
increased levels of SLE autoantibodies.19 Furthermore, in
patients with common variable immunodeﬁciency, levels of
switched memory cells are lower compared with controls.20 As
such low levels of switched and unswitched memory B cells are
associated with an unfavorable inﬂammatory status and, as we
Figure 2. High numbers of (un)switched memory cells associate with decreased risk of secondary
adverse cardiovascular events. Cox proportional hazard models are shown by tertiles of (un)switched
memory cells. The model is adjusted for age, sex, smoking, history of coronary artery disease, and
glomerular ﬁltration rate. The indicated P value is derived from comparison of highest to lowest tertile.
Figure 3. Serum IgG autoantibody titers directed
against oxLDL correlate with the numbers of
circulating class switched memory cells. Patients
are divided in tertiles by numbers of class switched
memory cells and corresponding IgG-a-oxLDL titers
are shown (P<0.01). Data are presented as mean
and error bars indicate SEM. Ig indicates
immunoglobulin; oxLDL, oxidized low-density
lipoprotein.
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show here for the ﬁrst time, with secondary cardiovascular
events in patients with severe atherosclerosis.
Similar to our observations regarding the memory B cells, it
has previously been shown that patients with high CD40+
B-cell percentages exhibit a lower stroke risk.22 Accordingly,
we also observed a lower rate of cerebrovascular events in
patients with high memory cell numbers (0.6%) compared with
patients with low numbers (3.6%). However, because of the
low prevalence of cerebrovascular events within our popula-
tion, we were not sufﬁciently powered to conﬁrm these
ﬁndings statistically.
The role of IgM antibodies in CVD has gained much
attention in the last decades. In mouse models, it was shown
that IgM secreted by B1 B cells was responsible for their
atheroprotective effect.28 In contrast to their role in mouse
studies,28,33 CD43+ B cells, suggested to resemble B1 cells in
mice,15 did not associate with protection against secondary
events in our study. Contrasting results have been reported
for the association of serum IgM levels with primary
cardiovascular events.51–53 In our study, patients with high
numbers of unswitched memory cells expressed more IgM on
their cell surface, suggesting an increased production and
release of IgM antibodies. However, it remains to be
elucidated whether the increase of surface IgM expression
translates to higher circulating IgM antibody levels and to
which antigens this IgM is directed. To investigate whether
the protective effect of memory B cells involves autoantibod-
ies directed against oxLDL, we measured oxLDL-speciﬁc titers
of IgM and IgG. IgM-a-oxLDL antibody titers were not different
between patients with and without a follow-up event, nor were
they associated with the number of unswitched memory B
cells. The number of class switched memory cells did show
signiﬁcant correlations with serum IgG-a-oxLDL antibody
titers, indicating that the switched memory cells might indeed
be responsible for the production of IgG-a-oxLDL antibodies.
However, IgG-a-oxLDL titers were not associated with the
occurrence of secondary CVD events, suggesting that oxLDL
antibodies are not responsible for the protective effect of
memory B cells in our population of severe atherosclerotic
patients. These data are in line with other observations that
also show no association with secondary CVD events,54,55 but
do not corroborate with other studies showing oxLDL
antibodies to be associated with occurrence and severity of
CVD.34–37 Apart from their pivotal role in antibody generation,
B cells can also regulate T-cell responses and produce
cytokines, suggesting a more-intricate role in cardiovascular
disease.14,56
In conclusion, we show that high numbers of unswitched
and switched memory B cells are associated with lower risk of
secondary cardiovascular events in a population with severe
CVD. These ﬁndings are based on a relatively small patient
cohort and should be established in larger patient cohorts.
However, our ﬁndings do suggest a potential role for B-cell
subsets in prediction and prevention of secondary cardiovas-
cular events in patients with atherosclerosis.
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